Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ)

Focus on targeted therapies

Alessandro Cappetta, Sara Lonardi, Davide Pastorelli, Francesca Bergamo, Giuseppe Lombardi, Vittorina Zagonel

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Despite recent improvements in surgical techniques and chemotherapy treatments, locally advanced/metastatic gastroesophageal junction (GEJ) and gastric cancer (GC) are still associated with poor clinical outcome. However, increased understanding of molecular mechanisms underlying carcinogenesis and its implementation in the treatment of breast, colon, lung, and other cancers in recent years have spurred focus on the development and incorporation of targeted agents in current therapeutic options for this difficult-to-treat disease. Such agents have the ability to target a variety of cancer relevant targets, including epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) and its receptor. In this review, we describe the current status of targeted therapies in the treatment of advanced GC and GEJ cancer, focusing on pre-clinical and clinical data available on monoclonal antibodies and tyrosine kinase inhibitors acting in these pathways, including completed and ongoing phase III studies.

Original languageEnglish
Pages (from-to)38-48
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Volume81
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Esophageal Neoplasms
Stomach Neoplasms
Therapeutics
Esophagogastric Junction
Vascular Endothelial Growth Factor Receptor
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Lung Neoplasms
Colon
Carcinogenesis
Breast
Monoclonal Antibodies
Drug Therapy
Neoplasms

Keywords

  • Gastric cancer
  • Gastro-oesophageal junction cancer
  • Monoclonal antibody
  • Targeted therapy
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

@article{77c27847eb994997b7b14ac85306d98d,
title = "Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): Focus on targeted therapies",
abstract = "Despite recent improvements in surgical techniques and chemotherapy treatments, locally advanced/metastatic gastroesophageal junction (GEJ) and gastric cancer (GC) are still associated with poor clinical outcome. However, increased understanding of molecular mechanisms underlying carcinogenesis and its implementation in the treatment of breast, colon, lung, and other cancers in recent years have spurred focus on the development and incorporation of targeted agents in current therapeutic options for this difficult-to-treat disease. Such agents have the ability to target a variety of cancer relevant targets, including epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) and its receptor. In this review, we describe the current status of targeted therapies in the treatment of advanced GC and GEJ cancer, focusing on pre-clinical and clinical data available on monoclonal antibodies and tyrosine kinase inhibitors acting in these pathways, including completed and ongoing phase III studies.",
keywords = "Gastric cancer, Gastro-oesophageal junction cancer, Monoclonal antibody, Targeted therapy, Tyrosine kinase inhibitor",
author = "Alessandro Cappetta and Sara Lonardi and Davide Pastorelli and Francesca Bergamo and Giuseppe Lombardi and Vittorina Zagonel",
year = "2012",
month = "1",
doi = "10.1016/j.critrevonc.2010.12.006",
language = "English",
volume = "81",
pages = "38--48",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ)

T2 - Focus on targeted therapies

AU - Cappetta, Alessandro

AU - Lonardi, Sara

AU - Pastorelli, Davide

AU - Bergamo, Francesca

AU - Lombardi, Giuseppe

AU - Zagonel, Vittorina

PY - 2012/1

Y1 - 2012/1

N2 - Despite recent improvements in surgical techniques and chemotherapy treatments, locally advanced/metastatic gastroesophageal junction (GEJ) and gastric cancer (GC) are still associated with poor clinical outcome. However, increased understanding of molecular mechanisms underlying carcinogenesis and its implementation in the treatment of breast, colon, lung, and other cancers in recent years have spurred focus on the development and incorporation of targeted agents in current therapeutic options for this difficult-to-treat disease. Such agents have the ability to target a variety of cancer relevant targets, including epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) and its receptor. In this review, we describe the current status of targeted therapies in the treatment of advanced GC and GEJ cancer, focusing on pre-clinical and clinical data available on monoclonal antibodies and tyrosine kinase inhibitors acting in these pathways, including completed and ongoing phase III studies.

AB - Despite recent improvements in surgical techniques and chemotherapy treatments, locally advanced/metastatic gastroesophageal junction (GEJ) and gastric cancer (GC) are still associated with poor clinical outcome. However, increased understanding of molecular mechanisms underlying carcinogenesis and its implementation in the treatment of breast, colon, lung, and other cancers in recent years have spurred focus on the development and incorporation of targeted agents in current therapeutic options for this difficult-to-treat disease. Such agents have the ability to target a variety of cancer relevant targets, including epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) and its receptor. In this review, we describe the current status of targeted therapies in the treatment of advanced GC and GEJ cancer, focusing on pre-clinical and clinical data available on monoclonal antibodies and tyrosine kinase inhibitors acting in these pathways, including completed and ongoing phase III studies.

KW - Gastric cancer

KW - Gastro-oesophageal junction cancer

KW - Monoclonal antibody

KW - Targeted therapy

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84855958099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855958099&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2010.12.006

DO - 10.1016/j.critrevonc.2010.12.006

M3 - Article

VL - 81

SP - 38

EP - 48

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -